Neomorph News and Resources

AbbVie has entered into a collaboration and option-to-license agreement with Neomorph, Inc. to advance the development of molecular glue degraders for oncology and immunology. The partnership aims to tackle challenging and historically “undruggable” protein targets by leveraging molecular glue degraders—a